What Is Fluconazole (Diflucan)?
Fluconazole is a triazole antifungal medication widely used to treat systemic and superficial fungal infections. Marketed under the brand name Diflucan (Pfizer), it is one of the most prescribed antifungal agents globally due to its excellent oral bioavailability, favorable safety profile, and broad spectrum of activity against Candida species and Cryptococcus neoformans.
Approved by the FDA in 1990, fluconazole is included on the World Health Organization’s Model List of Essential Medicines. It is available in oral capsules, oral suspension, and intravenous formulations, making it suitable for both outpatient and hospital settings. Its mechanism targets fungal cell membrane synthesis by inhibiting the enzyme lanosterol 14-alpha-demethylase, a key step in ergosterol production.
Mechanism of Action
Fluconazole selectively inhibits fungal cytochrome P450 14-alpha-demethylase (CYP51), an enzyme required for the conversion of lanosterol to ergosterol. Ergosterol is an essential component of the fungal cell membrane, regulating membrane fluidity and integrity. By depleting ergosterol and accumulating toxic sterol precursors, fluconazole disrupts membrane function, leading to fungal cell death.
Because human cells rely on cholesterol (not ergosterol) for membrane structure, fluconazole exhibits selective toxicity against fungi. It is primarily fungistatic against Candida species but may be fungicidal against Cryptococcus at higher concentrations. Resistance can develop through mutations in the ERG11 gene (encoding CYP51), efflux pump overexpression, or compensatory sterol pathway alterations.
Approved Uses and Indications
Fluconazole is FDA-approved for the following indications:
- Vaginal Candidiasis (Yeast Infection): Single oral dose of 150 mg. This is one of the most common indications, affecting approximately 75% of women at least once in their lifetime.
- Oropharyngeal and Esophageal Candidiasis (Thrush): Daily oral doses of 200–400 mg for 7–21 days depending on severity.
- Invasive Candidiasis: Including candidemia, intra-abdominal abscesses, and urinary tract infections caused by Candida species (except C. krusei and many C. glabrata strains).
- Cryptococcal Meningitis: A life-threatening fungal infection common in immunocompromised patients, especially those with HIV/AIDS. Fluconazole is used for both acute treatment (400–800 mg daily) and long-term maintenance therapy (200 mg daily).
- Prophylaxis: To reduce fungal infections in high-risk populations such as bone marrow transplant recipients, patients undergoing chemotherapy, and low-birth-weight neonates.
Off-label uses include treatment of dermatophyte infections (tinea corporis, tinea cruris, tinea pedis), blastomycosis, coccidioidomycosis (Valley fever), and histoplasmosis.
Dosage Forms and Administration
| Formulation | Strengths Available | Typical Adult Dosage | Duration |
|---|---|---|---|
| Capsules | 50 mg, 100 mg, 150 mg, 200 mg | 150 mg single dose (vaginal candidiasis) 200–400 mg daily (systemic infections) |
1 day to several weeks |
| Oral Suspension | 10 mg/mL, 40 mg/mL | Same as capsules; preferred for children and dysphagic patients | Variable |
| IV Solution | 2 mg/mL (200 mg/100 mL) | 400 mg IV loading dose then 200 mg IV daily | For hospitalized patients |
Note: Dosing adjustments are required in patients with renal impairment (creatinine clearance less than 50 mL/min). Fluconazole is heavily distributed into body tissues and fluids, including cerebrospinal fluid, vaginal secretions, and saliva, with concentrations reaching 50–90% of plasma levels.
Side Effects and Safety Profile
Fluconazole is generally well-tolerated. The most common side effects include headache, nausea, abdominal pain, diarrhea, dyspepsia, and dizziness. These are usually mild and resolve spontaneously.
Serious but rare adverse effects include hepatotoxicity (elevated liver enzymes to hepatitis and hepatic failure), QT interval prolongation (especially at high doses above 400 mg daily), exfoliative skin reactions (Stevens-Johnson syndrome), and anaphylaxis. Regular monitoring of liver function tests is recommended in patients receiving prolonged therapy or those with pre-existing liver disease.
Drug interactions are clinically significant. Fluconazole is a potent inhibitor of CYP2C9 and moderate inhibitor of CYP3A4, potentially increasing plasma concentrations of warfarin, phenytoin, sulfonylureas, statins (particularly atorvastatin and simvastatin), and oral contraceptives. Co-administration with terfenadine, cisapride, or pimozide is contraindicated due to risk of serious cardiac arrhythmias.
Comparison: Fluconazole vs. Other Antifungals
| Feature | Fluconazole | Itraconazole | Voriconazole | Clotrimazole (Topical) |
|---|---|---|---|---|
| Class | Triazole | Triazole | Triazole | Imidazole |
| Bioavailability | >90% oral | ~55% (variable) | ~96% oral | Topical only |
| CSF Penetration | Excellent | Poor | Good | N/A |
| Candida Coverage | Broad (not C. krusei) | Broad | Broadest azole | Limited to superficial |
| Aspergillus | No activity | Some activity | Active | No |
| Meningitis | Yes (Cryptococcus) | No | Yes (Aspergillus) | No |
Clinical Evidence and Efficacy
The clinical efficacy of fluconazole is supported by extensive randomized controlled trials and long-term post-marketing surveillance. In the treatment of vulvovaginal candidiasis, a single 150 mg oral dose achieves clinical cure rates of 80–90%, comparable to 7-day topical azole regimens but with superior patient convenience and compliance. A Cochrane meta-analysis of 15 trials involving 3,005 women confirmed equivalence between oral fluconazole and topical therapies for symptomatic yeast infections.
For oropharyngeal candidiasis in HIV-positive patients, daily fluconazole 200 mg achieves clinical response rates exceeding 90%, and maintenance therapy at 200 mg three times weekly prevents relapse effectively. In cryptococcal meningitis, the landmark ACTA trial demonstrated that fluconazole combined with flucytosine reduces mortality by 28% compared to fluconazole monotherapy, establishing combination therapy as standard in resource-limited settings where amphotericin B access is restricted.
Prophylactic use of fluconazole in high-risk ICU patients, supported by the ASPIRE trial series, showed a 25% reduction in invasive Candida infections. However, concerns about emerging resistance, particularly in non-albicans Candida species (C. glabrata and C. krusei), have led to recommendations for targeted rather than universal prophylaxis.
Antifungal Resistance
Antimicrobial resistance is an increasing concern with azole antifungals. Fluconazole resistance in Candida species has risen from less than 3% in the 1990s to approximately 10–15% in contemporary surveillance studies, with higher rates in C. glabrata (20–30%) and intrinsic resistance in C. krusei. Mechanisms include ERG11 gene mutations, overexpression of efflux pumps (CDR1, CDR2, MDR1), and biofilm formation. Susceptibility testing is recommended for patients with recurrent or refractory infections, particularly those with prior fluconazole exposure. Alternative antifungal classes, including echinocandins (caspofungin, micafungin) and amphotericin B, should be considered for resistant isolates. Reducing unnecessary antifungal use is critical to preserving fluconazole’s clinical utility.
Pediatric and Special Population Considerations
Fluconazole is approved for use in pediatric patients from birth, with dosing based on body weight. In neonates, the pharmacokinetics differ significantly from adults: lower clearance and larger volume of distribution necessitate modified dosing intervals. The NeoMero-1 trial provided data supporting the safety of fluconazole prophylaxis in very low-birth-weight infants to prevent invasive candidiasis. In elderly patients, renal function must be assessed, as fluconazole is predominantly excreted unchanged in urine, and dose adjustments are required when creatinine clearance falls below 50 mL/min. Hepatic impairment necessitates close monitoring of liver enzymes, with dose reduction considered in severe dysfunction.
India Generic Pricing Information
Fluconazole is available as an affordable generic medication from numerous Indian pharmaceutical companies including Cipla, Sun Pharma, Dr. Reddy’s Labs, Intas, and Zydus Cadila. The widespread availability of generic fluconazole in India has significantly reduced treatment costs globally.
Estimated Price Range in India (±10%):
- Fluconazole Capsules 150 mg (single dose pack): $1–$3 (Indian generic) vs. $15–$45 (US brand Diflucan)
- Fluconazole Capsules 200 mg (30 capsules): $7–$17 (Indian generic) vs. $180–$400 (US brand Diflucan)
- Fluconazole Oral Suspension 40 mg/mL (35 mL): $4–$10 (Indian generic) vs. $50–$120 (US brand Diflucan)
- Fluconazole IV 200 mg/100 mL (single vial): $9–$21 (Indian generic) vs. $90–$200 (US brand)
Note: Prices are approximate and may vary depending on the pharmacy, location, and applicable taxes. The ±10% range accounts for normal market fluctuations. International shipping and prescription requirements may affect final costs.
To explore generic antifungal options, visit our Pharmaceuticals product category.
Frequently Asked Questions
Safety Information and Precautions
Fluconazole is a prescription medication. Inform your healthcare provider about all medical conditions including liver disease, kidney disease, heart rhythm disorders (QT prolongation), and electrolyte abnormalities. Disclose all medications, supplements, and herbal products you take to avoid potentially dangerous interactions.
Immediately seek medical attention if you experience signs of liver injury (dark urine, jaundice, persistent nausea, abdominal pain), allergic reaction (rash, hives, difficulty breathing), or irregular heartbeat. Fluconazole suspension contains sucrose; diabetic patients should account for this in their carbohydrate management plan.
References
- Pappas PG, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the IDSA. Clinical Infectious Diseases, 2016; 62(4): e1–e50.
- Perfect JR, et al. Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the IDSA. Clinical Infectious Diseases, 2010; 50(3): 291–322.
- FDA Prescribing Information: Diflucan (fluconazole). U.S. Food and Drug Administration.
- UpToDate. “Pharmacology of azole antifungal agents.” Wolters Kluwer, 2024.
- World Health Organization. WHO Model List of Essential Medicines, 23rd List, 2023.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any new medication. Prices are approximate ranges (±10%) reflecting market variability. Generic medications should only be purchased from verified licensed pharmacies.
